A New, Non-Biologic Medication Option Being Tested For Those With Active Ankylosing Spondylitis: Results From a Phase 2 Clinical Trial for Filgotinib, a Selective Jack 1 Inhibitor.

A New, Non-Biologic Medication Option Being Tested For Those With Active Ankylosing Spondylitis: Results From a Phase 2 Clinical Trial for Filgotinib, a Selective Jack 1 Inhibitor.

By Spondylitis Association of America

A phase 2 clinical trial assessed the effectiveness and safety of an oral medication, Filgotinib, in patients with active ankylosing spondylitis (AS) who have not responded adequately to, or have been intolerant of, two or more non-steroidal anti-inflammatory drugs (NSAIDs).

SAA Launches New Juvenile Spondyloarthritis Website to Support Youth Impacted by the Chronic Disease

SAA Launches New Juvenile Spondyloarthritis Website to Support Youth Impacted by the Chronic Disease

By Spondylitis Association of America

On January 15, 2019, the Spondylitis Association of America will launch a dynamic new website for kids and teens impacted by juvenile spondyloarthritis (JSpA), a rheumatic disease that strikes before the age of 16 but may span throughout adulthood. The new website, Spondykids.org, will provide a wealth of educational information and resources for youth living with the disease and their families.

In Memoriam: Laurie M. Savage

In Memoriam: Laurie M. Savage

By Spondylitis Association of America

It is with heavy hearts and great sadness that we share the news of the passing of our dear friend, SAA’s former Executive Director, Laurie M. Savage, M.S. FLE. Laurie passed away on Sunday, December 30, 2018,  surrounded by her loving family, after her three-year-long battle with cancer. She fought cancer like she did everything else - with optimism and fearlessness - and a determination to not allow it to interfere with her life and passions.

Spondylitis Association of America Supports Research of Rheumatic Disease Impacting 3 Million Americans

Spondylitis Association of America Supports Research of Rheumatic Disease Impacting 3 Million Americans

By Spondylitis Association of America

Since its founding more than 35 years ago, the Spondylitis Association of America (SAA) has been at the forefront of funding research for a cure for spondyloarthritis (SpA). Embracing its mission to be the leading national nonprofit in the fight for a cure and to advocate on behalf of all people impacted by the chronic illness, SAA continues to identify and support ground-breaking research projects through its SAA/Bruckel Early Career Investigator Award in AxSpA (ECI) and additional grants for exploratory research.

Help researchers determine best methods of measuring and tracking spinal fusion in ankylosing spondylitis

Help researchers determine best methods of measuring and tracking spinal fusion in ankylosing spondylitis

By Spondylitis Association of America

Better ways to measure spinal fusion are needed to be able to evaluate the effectiveness of medicines in slowing or stopping spinal fusion. This study hopes to answer the question of whether CT scanning of the spine can provide a reliable, valid, and sensitive measure of spinal fusion in ankylosing spondylitis.

RSS
12345678910Last

Stay Informed

Text/HTML

Careers

Visit our careers page for available positions

Contact Us

Spondylitis Association of America

16360 Roscoe Blvd.  Ste. 100
Van Nuys, CA 91406

Email

info@spondylitis.org

Information Requests

(800) 777-8189 U.S. only
or (818) 892-1616
*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.

Give With Confidence

Independent Charities of America